{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:03:59Z","timestamp":1789625039218,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The pharmacokinetics of meropenem in pediatric patients have large interindividual variability. Model-informed precision dosing (MIPD) is a promising way to ensure optimal exposure but relies on a population pharmacokinetic (PPK) model. This review systemically synthesized the available PPK model for meropenem in pediatric patients to facilitate MIPD in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four electronic databases were searched for eligible studies that reported the use of the meropenem PPK model for pediatric patients. The study design information, patient characteristic demography, PPK modeling strategy and final PPK parameter estimates were extracted and reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty studies published from 2006 to 2025 were included in the analysis. Fourteen studies had prospective designs, and four studies were international multicenter studies. Seven studies applied an intensive sampling strategy. Pediatric patients with various characteristics were included, and most had severe infections or were admitted to the ICU. Four studies focused on patients with organ support, mainly renal replacement and extracorporeal membrane oxygenation. The sample sizes were usually small (sample sizes no more than 50). Fourteen studies ultimately obtained the 2-CMT model, and the remaining studies used the 1-CMT model, except for one 3-CMT model. Body weight, age and renal function indicators were the most common covariates. The typical CL values ranged from 0.50\u201313.22\u202fL\/h or 0.122\u20130.526\u202fL\/h\/kg. The Vcs for the 2-CMT models ranged from 0.969\u201321.4\u202fL or 0.272\u20130.57\u202fL\/kg. Most models underwent internal validation, but only one study performed external validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study successfully integrated the current meropenem PPK models for pediatric patients, which would benefit the clinical application of MIPD. Clinicians should select appropriate models on the basis of patient characteristics carefully, and therapeutic drug monitoring is important at the current stage. External validation and well-designed studies on specific subpopulations, such as patients with organ support, neonates, and specific disease status, are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO, identifier (CRD420261481301).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1897237","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:34:18Z","timestamp":1789623258000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetic model for meropenem in pediatric patients: a systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Huaping","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]},{"name":"Research Center for Clinical Pharmacy, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Affiliated Xiaoshan Hospital, Hangzhou Normal University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]},{"name":"Research Center for Clinical Pharmacy, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Xia","sequence":"additional","affiliation":[{"name":"Affiliated Xiaoshan Hospital, Hangzhou Normal University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1521091","DOI":"10.3389\/fcimb.2025.1521091","article-title":"Enhancing antibiotic therapy through comprehensive pharmacokinetic\/pharmacodynamic principles","volume":"15","author":"Alikhani","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12941-019-0320-2","article-title":"Antimicrobial consumption in three pediatric and neonatal intensive care units in Saudi Arabia: 33-month surveillance study","volume":"18","author":"Balkhy","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40262-024-01465-1","article-title":"Population pharmacokinetics of meropenem across the adult lifespan","volume":"64","author":"Boutzoukas","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1097\/PCC.0000000000003698","article-title":"Subtherapeutic meropenem antibiotic exposure in children with septic shock assessed by noncompartmental pharmacokinetic analysis in a prospective dataset","volume":"26","author":"Bradley","year":"2025","journal-title":"Pediatr. Crit. Care Med."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/INF.0b013e318170f8d2","article-title":"Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate","volume":"27","author":"Bradley","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e0172923","DOI":"10.1128\/aac.01729-23","article-title":"How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children","volume":"68","author":"Butrague\u00f1o-Laiseca","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5863\/1551-6776-22.4.276","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children","volume":"22","author":"Cies","year":"2017","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0091270005283283","article-title":"Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients","volume":"46","author":"Du","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/cpdd.1395","article-title":"Nlmixr2 versus NONMEM: An evaluation of maximum a posteriori Bayesian estimates following external evaluation of gentamicin and tobramycin population pharmacokinetic models","volume":"13","author":"Duong","year":"2024","journal-title":"Clin. Pharmacol. drug Dev."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s13318-025-00960-5","article-title":"Population pharmacokinetic model evaluation with a small real-world dataset versus a large virtual dataset: does sample size affect decision-making?","volume":"50","author":"El Hassani","year":"2025","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/17512433.2023.2288171","article-title":"Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses","volume":"16","author":"Goulooze","year":"2023","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e0185422","DOI":"10.1128\/spectrum.01854-22","article-title":"In vitro activity of new \u03b2-lactam-\u03b2-lactamase inhibitor combinations and comparators against clinical isolates of gram-negative bacilli: results from the China antimicrobial surveillance network (CHINET) in 2019","volume":"10","author":"Guo","year":"2022","journal-title":"Microbiol. Spectrum"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10156-009-0025-0","article-title":"Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients","volume":"16","author":"Ikawa","year":"2010","journal-title":"J. Infect. Chemother."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40262-013-0114-1","article-title":"Reporting a population pharmacokinetic\u2013pharmacodynamic study: a journal\u2019s perspective","volume":"53","author":"Jamsen","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/jac\/dkae274","article-title":"Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation","volume":"79","author":"Junior","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","article-title":"Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement","volume":"54","author":"Kanji","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijantimicag.2016.04.025","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection","volume":"48","author":"Kongthavonsakul","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3390\/ph19071090","article-title":"Advancing pediatric dose scaling: strategies, modeling approaches, and clinical applications","volume":"19","author":"Kudgus Lokken","year":"2026","journal-title":"Pharmaceuticals"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40262-025-01495-3","article-title":"Variability in meropenem distribution and clearance in children with sepsis: population - based pharmacokinetics with assessment of renal biomarkers","volume":"64","author":"Le","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.anpede.2024.05.001","article-title":"Therapeutic drug monitoring of antibiotic and antifungical drugs in paediatric and newborn patients. Consensus guidelines of the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Paediatric Infectious Diseases (SEIP)","volume":"101","author":"Luque","year":"2024","journal-title":"Anales de Pediatr\u00eda (English Edition)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/jac\/dkab494","article-title":"Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, phase 3 trial comparing ceftolozane\/tazobactam and meropenem for treatment of hospital-acquired\/ventilator-associated bacterial pneumonia","volume":"77","author":"Martin-Loeches","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"107186","DOI":"10.1016\/j.ijantimicag.2024.107186","article-title":"Treatment of infections caused by multidrug-resistant gram-negative bacilli: a practical approach by the Italian (SIMIT) and French (SPILF) societies of infectious diseases","volume":"64","author":"Meschiari","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"102634","DOI":"10.1016\/j.jiac.2025.102634","article-title":"Impact of prolonged versus intermittent infusion of meropenem on mortality and clinical outcomes in patients with severe infection: a systematic review and meta-analysis","volume":"31","author":"Mu","year":"2025","journal-title":"J. Infect. Chemother."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2133\/dmpk.DMPK-11-RG-027","article-title":"Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic\/pharmacodynamic considerations","volume":"26","author":"Ohata","year":"2011","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ijantimicag.2019.06.021","article-title":"Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis","volume":"54","author":"Ohata","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.mcna.2025.01.003","article-title":"Management of Severe Infections: multidrug-resistant and carbapenem-resistant gram-negative Bacteria","volume":"109","author":"Perez","year":"2025","journal-title":"Med. Clin. North Am."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/jac\/dkv289","article-title":"Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis","volume":"71","author":"Pettit","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3390\/antibiotics13050419","article-title":"Meropenem disposition in neonatal and Pediatric extracorporeal membrane oxygenation and continuous renal replacement therapy","volume":"13","author":"Pokorn\u00e1","year":"2024","journal-title":"Antibiotics"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"106368","DOI":"10.1016\/j.ijantimicag.2021.106368","article-title":"Antibiotic pharmacokinetic\/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond","volume":"58","author":"Rao","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e01909","DOI":"10.1128\/AAC.01909-20","article-title":"Population pharmacokinetics and pharmacodynamics of meropenem in critically ill Pediatric patients","volume":"65","author":"Saito","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.medmal.2020.01.001","article-title":"Comparative review of imipenem\/cilastatin versus meropenem","volume":"50","author":"Salmon-Rousseau","year":"2020","journal-title":"Med. Mal. Infect."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/BF03261932","article-title":"Fundamentals of population pharmacokinetic modelling: validation methods","volume":"51","author":"Sherwin","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/INF.0b013e31822e8b0b","article-title":"Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections","volume":"30","author":"Smith","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40262-021-01069-z","article-title":"Age-related change in hepatic clearance inferred from multiple population pharmacokinetic studies: comparison with renal clearance and their associations with organ weight and blood flow","volume":"61","author":"Soejima","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"889958","DOI":"10.3389\/fped.2022.889958","article-title":"Antimicrobial dosing recommendations in Pediatric continuous renal replacement therapy: a critical appraisal of current evidence","volume":"10","author":"Stitt","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1159\/000534828","article-title":"Pharmacokinetic research in Pediatric extracorporeal therapies: current state and future directions","volume":"53","author":"Stitt","year":"2024","journal-title":"Blood Purif."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e27266","DOI":"10.1097\/MD.0000000000027266","article-title":"Comparative efficacy and safety of antipseudomonal \u03b2-lactams for pediatric febrile neutropenia: a systematic review and Bayesian network meta-analysis","volume":"100","author":"Tan","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e70438","DOI":"10.1111\/cts.70438","article-title":"Building a Beta-lactam model-informed precision dosing Service in a Quaternary Care Children\u2019s hospital","volume":"18","author":"Tang Girdwood","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/cpt.2065","article-title":"A model averaging\/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study","volume":"109","author":"Uster","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1128\/AAC.00351-09","article-title":"Meropenem pharmacokinetics in the newborn","volume":"53","author":"Van Den Anker","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e00760-20","DOI":"10.1128\/AAC.00760-20","article-title":"Reappraisal of the optimal dose of meropenem in critically ill infants and children: a developmental pharmacokinetic- pharmacodynamic analysis","volume":"64","author":"Wang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"699191","DOI":"10.3389\/fphar.2021.699191","article-title":"Optimized dosing regimens of meropenem in septic children receiving extracorporeal life support","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1208\/s12249-021-02076-w","article-title":"Physiologically based pharmacokinetic models are effective support for Pediatric drug development","volume":"22","author":"Wang","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3390\/children9121998","article-title":"Developmental population pharmacokinetics-pharmacodynamics of meropenem in Chinese neonates and young infants: dosing recommendations for late-onset sepsis","volume":"9","author":"Wu","year":"2022","journal-title":"Children"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijid.2021.08.031","article-title":"Population pharmacokinetics of meropenem in critically ill infant patients","volume":"111","author":"Yonwises","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"709332","DOI":"10.3389\/fphar.2021.709332","article-title":"Population pharmacokinetics of vancomycin and meropenem in Pediatric extracorporeal membrane oxygenation support","volume":"12","author":"Zylbersztajn","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1897237\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:34:19Z","timestamp":1789623259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1897237\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":49,"alternative-id":["10.3389\/fmicb.2026.1897237"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1897237","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1897237"}}